TFF Pharmaceuticals Announces Engagement of J.S. Cole & Associates as Strategic Advisor for Partnering Efforts in Japan
March 12 2020 - 9:00AM
Business Wire
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative drug products based on its patented Thin Film Freezing
(TFF) technology platform, today announced that the Company has
engaged J.S. Cole & Associates to serve as exclusive financial
advisor for the Company’s partnering efforts in Japan.
J.S. Cole & Associates provides business development and
marketing research services for pharmaceutical, biotechnology,
medical device, and diagnostic companies. The company has worked as
liaison for both licensees and licensors in the US, the Far East,
and Europe, with a particular emphasis and knowledge of the
Japanese healthcare industry, its landscape and its
initiatives.
“In our efforts to expand business development and partnering
outreach in the Far East, we are very pleased to have J.S. Cole
& Associates on board with us,” said Glenn Mattes, President
& CEO of TFF Pharmaceuticals. “Their long-term ties and
personal contacts with some of the leading biotech and
pharmaceutical companies in Japan will be a strategic advantage for
us as we look to partner our technology platform in this important
and growing market.”
“TFF’s technology and platform is both disruptive and a
potentially strong fit with many biopharmaceutical companies in
Japan,” said Steven Cole, President of J.S. Cole Associates. “We
look forward to introducing the Company and its technology to
potential partners, joint ventures, or other strategic alliances in
this important and growing market.”
About J.S. Cole & Associates J.S. Cole &
Associates provides business development and marketing research
services for pharmaceutical, biotechnology, medical device, and
diagnostic companies. For over 15 years, the company has been
working as liaisons for both licensees and licensors in the US,
Japan, and Europe resulting in dozens of finalized deals including
a significant number in Japan. For more information, please visit
http://www.coleconsult.com
About TFF Pharmaceuticals’ Thin Film Freezing technology
platform TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform
was designed to improve the solubility and absorption of poorly
water-soluble drugs and is particularly suited to generate dry
powder particles with properties targeted for inhalation delivery,
especially to the deep lung, an area of extreme interest in
respiratory medicine. The TFF process results in a “Brittle Matrix
Particle,” which possesses low bulk density, high surface area, and
typically an amorphous morphology, allowing the particles to
supersaturate when contacting the target site, such as lung tissue.
Based upon laboratory experiments, the aerodynamic properties of
the particles are such that the portion of a drug deposited to the
deep lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals TFF Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative drug products based on its patented Thin
Film Freezing, or TFF, technology platform. Early testing confirms
that the TFF platform can significantly improve the solubility and
absorption of poorly water-soluble drugs, a class of drugs that
comprises approximately one-third of the major pharmaceuticals
worldwide, thereby improving their pharmacokinetics. TFF
Pharmaceuticals has two lead drug candidates: Voriconazole
Inhalation Powder and Tacrolimus Inhalation Powder. The Company
plans to add to this pipeline by collaborating with large
pharmaceutical partners. The TFF Platform is protected by 39
patents issued or pending in the US and internationally. To learn
more about TFF Pharmaceuticals and its product candidates, visit
the Company’s website at https://tffpharma.com.
SAFE HARBOR This press release contains forward-looking
statements regarding TFF Pharmaceuticals, Inc., including the
development of potential business partnership in Japan through J.S.
Cole & Associates, the benefits of the Company’s TFF platform
and its dry powder version of Voriconazole and Tacrolimus, and the
Company’s plans to add to its existing pipeline of product
candidates. Those forward-looking statements involve known and
unknown risks, uncertainties and other factors that could cause
actual results to differ materially. Among those factors are: (i)
no drug product incorporating the TFF platform has received FDA
pre-market approval or otherwise been incorporated into a
commercial drug product, (ii) the Company has no current agreements
or understandings with any large pharmaceutical companies for the
development of a drug product incorporating the TFF Platform and
(iii) those other risks disclosed in the section “Risk Factors”
included in the Company’s Quarterly Report on Form 10-Q filed with
the on December 9, 2019. TFF Pharmaceuticals cautions readers not
to place undue reliance on any forward-looking statements. TFF
Pharmaceuticals does not undertake, and specifically disclaims, any
obligation to update or revise such statements to reflect new
circumstances or unanticipated events as they occur, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200312005406/en/
Company Contacts: Glenn Mattes President and CEO TFF
Pharmaceuticals, Inc. gmattes@tffpharma.com 737-802-1973 Kirk
Coleman Chief Financial Officer TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com 817-989-6358 Investor Relations and Media
Contact: Paul Sagan LaVoieHealthScience
psagan@lavoiehealthscience.com 617-953-4779
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Mar 2024 to Apr 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Apr 2023 to Apr 2024